Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp. (EMBC) generates a steady stream of news as a global diabetes care and medical supplies company listed on The Nasdaq Global Select Market. The company describes itself as advancing a 100-year legacy in insulin delivery and working to transform from an insulin delivery company into a broader medical supplies company. News about embecta often reflects this strategic evolution and its role in diabetes care worldwide.
Investors and observers can expect frequent updates tied to financial performance, including quarterly and full-year earnings results. embecta regularly issues press releases detailing revenues by geography and product family, operating margins, adjusted metrics, and guidance for upcoming fiscal years. These announcements are often accompanied by commentary on business drivers such as product volumes, pricing, foreign currency effects, and contract manufacturing activity.
Another key category of news covers strategic initiatives and partnerships. embecta has highlighted its global ERP implementation, brand transition from BD-branded to embecta-branded injection devices, and restructuring efforts aimed at improving profitability and reducing debt. The company also reports on collaborations with pharmaceutical partners to co-package embecta pen needles with potential generic GLP-1 therapies, as well as humanitarian partnerships, including large-scale donations of pen needles and insulin syringes through organizations such as Direct Relief.
embecta’s news flow also includes corporate governance and capital allocation topics, such as board changes, upcoming investor conferences, and regular announcements of quarterly cash dividends. Together, these updates provide insight into how embecta manages its diabetes-focused portfolio, pursues growth opportunities, and communicates with stockholders. For readers tracking EMBC, this news page offers an organized view of the company’s financial disclosures, strategic milestones, and corporate developments over time.
Embecta (Nasdaq: EMBC) will present at the 2026 BofA Securities Global Health Care Conference in Las Vegas on May 13, 2026 at 3:00 p.m. PT / 6:00 p.m. ET. Audio webcasts will be available via the News & Events section of the company's investor relations site at investors.embecta.com.
embecta (Nasdaq: EMBC) declared a quarterly cash dividend of $0.01 per share. The dividend is payable on June 15, 2026 to shareholders of record at the close of business on May 28, 2026.
Embecta (Nasdaq: EMBC) reported second quarter fiscal 2026 financial results and announced an analyst and investor conference call and live webcast on May 5, 2026 at 8:00 a.m. ET. A webcast replay will be available beginning at 11:00 a.m. ET on May 5, 2026 and archived for one year on the investor website.
Investors are directed to the company investor relations site for the full earnings press release and presentation.
embecta (Nasdaq: EMBC) will report fiscal second quarter 2026 results and host a live conference call and webcast on May 5, 2026 at 8:00 a.m. ET. A replay will be available beginning at 11:00 a.m. ET on the embecta investor relations website and archived for one year.
embecta (Nasdaq: EMBC) agreed to acquire UK-based Owen Mumford for up to £150 million—£100 million upfront plus up to £50 million in performance payments tied to Aidaptus® sales over three years. The deal is expected to close in embecta’s fiscal Q3 2026, subject to approvals.
The acquisition adds drug-delivery platforms, a £69.4M FY2025 revenue base, manufacturing capabilities and global commercial reach to accelerate embecta’s transformation into a broad-based medical supplies company.
embecta (Nasdaq: EMBC) announced board leadership changes effective February 11, 2026: Devdatt "Dev" Kurdikar was elected Chairman of the Board and Dr. Claire Pomeroy was elected Lead Independent Director. These changes follow the retirement of LTG (Ret.) David F. Melcher.
Kurdikar joins as chairman after serving as president and CEO of a diabetes care spinoff since 2022. Dr. Pomeroy will continue to chair the Corporate Governance and Nominating Committee and serve on the Technology, Quality and Regulatory Committee.
Embecta (Nasdaq: EMBC) reported first quarter fiscal 2026 financial results on February 5, 2026. The company directs investors to its Investor Relations website for the detailed earnings release and presentation.
Embecta hosted a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET on February 5, 2026, with a replay available beginning at 11:00 a.m. ET on February 5, 2026 and archived for one year on the investor relations site.
embecta (Nasdaq: EMBC) declared a quarterly cash dividend of $0.15 per share. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. This applies to all issued and outstanding common shares.
embecta (Nasdaq: EMBC) will report fiscal first quarter 2026 results and host a conference call on Thursday, February 5, 2026 at 8:00 a.m. ET. The call will include an operational update and a Q&A session. Investors can access a live webcast or teleconference, and a webcast replay will be available beginning at 11:00 a.m. ET on February 5, 2026 and archived on the embecta investor relations website for one year.
Embecta (Nasdaq: EMBC) said management will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT / 5:15 p.m. ET. Audio webcasts of the presentations will be available in the News & Events section of the company's investor relations website at investors.embecta.com.